Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 Mono- or Combination Therapy in Advanced ESCC
NCT05221658Phase 2Unknown
- Sponsor
- Henlius
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenosquamous carcinoma (ASC), sponsored by Henlius. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on NCT05221658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221658.